

FOR IMMEDIATE RELEASE

ACC Commercially Launches Fungitell QS™, a New Integrated Platform for Fungitell STAT® Testing

East Falmouth, MA — September 30, 2026 — Associates of Cape Cod, Inc. (ACC) will soon introduce Fungitell QS™, a new fully integrated system designed exclusively for use with Fungitell STAT®, ACC's rapid (1→3)-β-D-glucan test for invasive fungal infection screening.

Debuting shortly, Fungitell STAT® using Fungitell QS™ will bring greater flexibility and control to rapid (1→3)-β-D-glucan testing. The compact system combines a 10-well incubating tube reader, separate 10-well incubation station, touchscreen, integrated software, and local data storage, eliminating the need for a separate computer.

With Fungitell QS™, technicians can begin testing samples as they arrive and add new samples to available wells while other tests are in progress. This open-access workflow can get results into clinicians' hands sooner, supporting timely clinical decision-making and patient care.

Fungitell QS™ also provides early identification of certain results. Samples with high optical interference can be identified within seconds after insertion, while above-range positive results may be reported in approximately 12 minutes when a valid Fungitell STAT® Standard is stored in the system.

Additional features include:

- A compact footprint of approximately 11.2 inches wide × 11.3 inches deep × 3.7 inches high
- A searchable local database that stores up to 10,000 test results
- QC status, Index, Sample Category, and estimated Fungitell pg/mL result information
- USB barcode scanner and printer accessories to support data entry and result output
- LIMS-compatible CSV output
- USB and Ethernet data-transfer options

“For decades, ACC has worked to advance diagnostic solutions that help laboratories detect invasive fungal infections and support timely clinical decision-making,” said Dr. AJ Meuse, President and Chief Executive Officer of ACC. “Fungitell QS™ builds on that legacy

and represents the next step in our continued commitment to making rapid fungal testing more flexible, integrated, and responsive to laboratory and clinical needs.”

Fungitell QS™ enhances and simplifies Fungitell STAT® testing giving users a more integrated testing experience by enabling continuous sample processing. The software saves the standard’s data, allowing you to remove all tubes to free up wells for new incoming samples while keeping the assay live. The new platform adds updated instrumentation, integrated software, open access, and expanded capabilities to a familiar workflow.

ACC will provide technical support and training to help users integrate Fungitell QS™ into their testing workflow.

Learn More

ACC will be showcasing the Fungitell QS™ platform at ID Week in Washington, DC October 22-24, 2026. Laboratories interested in learning more about Fungitell STAT® using Fungitell QS™, preparing for adoption, or receiving availability updates can contact ACC at <https://acciusa.com/contact-us/>.

About ACC — A Seikagaku Group Company

Specializing in recombinant and traditional chromogenic and turbidimetric reagent technologies, ACC has been a global leader in endotoxin and (1,3)-β-D-glucan detection products and services for over 50 years. ACC pioneered modern LAL testing methodology and was the first U.S. FDA-licensed company to manufacture LAL reagents; ACC is today recognized as an international leader in endotoxin detection. Visit www.acciusa.com for more information.

About Fungitell STAT®

Fungitell STAT® is the first and only single-sample format FDA-cleared and CE-marked rapid *in vitro* diagnostic screening test for invasive fungal infection, including *Candida*, *Aspergillus*, and *Pneumocystis*, that detects (1→3)-β-D-glucan in serum.

All trademarks are the property of their respective owners.

For further information, contact:

Vann Jones – Director, Global Marketing & Commercial Strategy
vjones@acciusa.com